Sec Form 4 Filing - O'Connor Daniel J. @ ONCOSEC MEDICAL Inc - 2017-09-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person O'Connor Daniel J. 2. Issuer Name and Ticker or Trading Symbol ONCOSEC MEDICAL Inc [ ONCS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO (Last) (First) (Middle) C/O ONCOSEC MEDICAL INCORPORATED, 5820 NANCY RIDGE DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 09/01/2017 (Street) SAN DIEGO, CA92121 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 1.25 ( 1 ) 01/12/2018( 2 ) A 2,000,000 ( 3 ) 01/12/2018 11/07/2027 Common Stock 2,000,000 ( 4 ) $ 0 2,000,000 D Stock Option (Right to Buy) $ 1.25 ( 1 ) 01/12/2018( 2 ) A 500,000 ( 3 ) 01/12/2018 11/07/2027 Common Stock 500,000 ( 5 ) $ 0 500,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other O'Connor Daniel J. C/O ONCOSEC MEDICAL INCORPORATED 5820 NANCY RIDGE DRIVE SAN DIEGO, CA92121 X CEO Signatures /s/ Daniel J. O'Connor 01/17/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )OncoSec's (ONCS) stock closing price was $1.25 on November 7, 2017. ( 2 )The above listed Stock Options were approved by OncoSec's stockholders at OncoSec's Annual Stockholders Meeting held on January 12, 2018. ( 3 )The shares subject to the stock option were approved by the Company's Board of Directors on November 7, 2017 ("Grant Date"), contingent upon approval by the Company's stockholders at the Company's Annual Stockholders Meeting on January 12, 2018. ( 4 )One million (1,000,000) Options vested upon the Company's stockholders' approval of the Option at the Company's Annual Stockholders Meeting held on January 12, 2018 and one twenty-fourth (1/24th) of the remaining one million (1,000,000) Options shall vest on each monthly anniversary of the date of the Grant Date. ( 5 )The stock option were approved by the Company's Board of Directors on November 7, 2017 ("Grant Date"), subject to stockholder approval and the Company's stockholders approved the grant at the Company's Annual Stockholders Meeting on January 12, 2018. Subject to the terms of the Company's 2011 Stock Incentive Plan and related award agreement, two hundred fifty thousand (250,000) of the options shall be fully vested on the date that the Company achieves one hundred percent (100%) enrollment in the first cohort of the Pisces Study (the "Enrollment Date") and the remaining two hundred fifty thousand (250,000) PISCES Options shall vest on the first anniversary of the Enrollment Date, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.